MAPLE GROVE, Minn., Sept. 20, 2018 /PRNewswire/ -- Pursuit Vascular, Inc., manufacturer of ClearGuard® HD Antimicrobial Barrier Caps, the leading antimicrobial device for catheter-based dialysis patients, today announced that Greg Walpole has joined the company as vice president of sales. In his new role, Walpole will lead sales activities for the company in North America, including a team of 4 sales directors.
Walpole was formerly with Ecomed Solutions, where he was sales manager for the past two years, leading sales activities and distribution partners for the company's line of IV components and niche market IV products.
Prior to this, Walpole led sales for the Renal Products division of ICU Medical for 9 years until 2014, where he led the company's commercial sales launch and sales team for the Tego® Needlefree Connector product line. In the renal field, the Tego connector is used in catheter-based dialysis patients in between procedures to prevent infection. Under Walpole's leadership, U.S. sales of the Tego connector into dialysis inpatient and outpatient accounts grew significantly, as did the number of distribution partners. In total, Walpole was with ICU Medical for 15 years.
"We are very pleased to have a sales executive of Greg's stature join us at Pursuit Vascular as we work to make our ClearGuard HD product a standard of care for catheter-based dialysis patients worldwide. His leadership skills and industry experience make him a perfect fit to lead our sales team," said Doug Killion, Pursuit Vascular President and CEO.
"I'm very happy to join Pursuit Vascular," said Walpole. "The ClearGuard HD product line is a proven therapy for dialysis patients who dialyze using a catheter, and who are frequently plagued by deadly bloodstream infections. Getting this product into broad use as quickly as possible is the company's goal, and I am proud to be a part of that mission."
Walpole is a graduate of University of Texas at Dallas and will be based in Dallas.
About the ClearGuard HD Antimicrobial Barrier Cap
The ClearGuard HD Antimicrobial Barrier Cap is the first and only device cleared for sale in the U.S. that kills infection-causing bacteria inside a long-term hemodialysis catheter hub. The caps are simple to use and clinically shown to reduce central line-associated bloodstream infection. This simple, yet revolutionary single-use device is protected by 8 issued U.S. patents, and several other U.S. patents pending. Foreign patents issued and pending. For more information, visit www.clearguardhd.com.
About Pursuit Vascular
Headquartered in Maple Grove, Minnesota, Pursuit Vascular, Inc. (www.pursuitvascular.com) is developing a family of innovative products designed to protect patients from acquiring life-threatening infections associated with long-term catheter and port use, while reducing the costs of health care.
Connect with us at www.pursuitvascular.com and on Twitter at @ClearGuardHD.
SOURCE Pursuit Vascular, Inc.